Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
6 papers
Recent·Most cited
P. Gupta, S. E. Thomas, J. Cory-Wright…·V. Mendes
This study uses a fragment-based approach to assess the ligandability of four enzymes in the L-arginine biosynthesis pathway of M. tuberculosis, identifying potential drug targets.
J. El Bakali, M. Blaszczyk, J. C. Evans…·C. Spry
This study identifies inhibitors of MtbPPAT, a key enzyme in CoA biosynthesis, using fragment linking and CRISPR interference to validate it as a potential anti-TB drug target.
D. E. Scott, N. J. Francis-Newton, M. E. Marsh…·C. Abell
The paper identifies CAM833, a small-molecule inhibitor of BRCA2-RAD51 interaction, which disrupts RAD51 assembly and enhances DNA damage-induced cell death in BRCA2-wildtype cells.
J. A. Ribeiro, A. Hammer, G. A. L. Zuniga…·M. V. B. Dias
This study uses fragment-based drug discovery to identify novel chemical scaffolds targeting Mycobacterium tuberculosis DHFR, revealing a new binding mode and low micromolar affinity compounds.
V. Mendes, S. R. Green, J. C. Evans…·T. L. Blundell
The paper identifies potent inhibitors of Mycobacterium tuberculosis CoaB by targeting a novel allosteric site, based on structural and biochemical analyses of CoaBC.
S. E. Thomas, A. J. Whitehouse, K. Brown…·V. Mendes
This study identifies new TrmD inhibitors for mycobacterial infections using fragment-based drug discovery, showing activity against multiple mycobacterial species in vitro and in macrophage models.